// test_skyflow_data.json

{
  "condition": "leukemia",
  "studies": [
    {
      "nct_id": "NCT12345",
      "title": "B-cell Acute Lymphoblastic Leukemia Treatment Study",
      "status": "RECRUITING",
      "phase": ["PHASE3"],
      "conditions": ["B-cell Acute Lymphoblastic Leukemia", "Relapsed Refractory Leukemia"],
      "lead_sponsor": "[NAME_VGMgLRv]",
      "investigators": ["[NAME_Jgf3GNQ]", "[NAME_BuVLer5]"],
      "sites": ["[LOCATION_ADDRESS_STREET_S5USJli], Columbus, OH 43221"],
      "patient_demographics": {
        "age": 46,
        "sex": "Male",
        "race": "White"
      },
      "medical_history": {
        "diagnosis": "B-ALL relapsed refractory",
        "initial_diagnosis": "2022",
        "relapse_date": "2024",
        "current_blasts": "58 percent CD19+, CD22+",
        "cytogenetics": "t(12;21)(p13;q22), IKZF1 deletion",
        "mutations": "NRAS G12D, TP53 R248Q (5% VAF)"
      },
      "treatment_history": [
        "hyper-CVAD induction (2022)",
        "blinatumomab consolidation (2 cycles)",
        "inotuzumab ozogamicin (partial response)"
      ],
      "current_symptoms": [
        "progressive fatigue",
        "night sweats", 
        "lymphadenopathy",
        "cytopenias"
      ],
      "lab_results": {
        "hemoglobin": "7.4 g/dL",
        "wbc": "2.8 K/uL",
        "platelets": "61 K/uL",
        "creatinine": "0.9 mg/dL"
      },
      "summary": "46-year-old male with relapsed refractory B-cell ALL. Previously treated with hyper-CVAD, blinatumomab, and inotuzumab. Current presentation with progressive fatigue, night sweats, and cytopenias. Bone marrow shows 58% blasts with high-risk cytogenetics."
    }
  ]
}